- Home
- ONCO vs ADXN Comparison
ONCO vs ADXN Comparison
Compare ONCO & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- ADXN
- Stock Information
- Founded
- ONCO 2018
- ADXN 2002
- Country
- ONCO United States
- ADXN Switzerland
- Employees
- ONCO N/A
- ADXN N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- ADXN Health Care
- Exchange
- ONCO Nasdaq
- ADXN Nasdaq
- Market Cap
- ONCO 1.8M
- ADXN 10.1M
- IPO Year
- ONCO 2022
- ADXN N/A
- Fundamental
- Price
- ONCO $4.23
- ADXN $8.83
- Analyst Decision
- ONCO
- ADXN Strong Buy
- Analyst Count
- ONCO 0
- ADXN 1
- Target Price
- ONCO N/A
- ADXN $30.00
- AVG Volume (30 Days)
- ONCO 233.6K
- ADXN 14.6K
- Earning Date
- ONCO 08-28-2025
- ADXN 08-11-2025
- Dividend Yield
- ONCO N/A
- ADXN N/A
- EPS Growth
- ONCO N/A
- ADXN N/A
- EPS
- ONCO N/A
- ADXN 0.10
- Revenue
- ONCO $1,925,313.00
- ADXN $278,508.00
- Revenue This Year
- ONCO N/A
- ADXN $86.57
- Revenue Next Year
- ONCO N/A
- ADXN N/A
- P/E Ratio
- ONCO N/A
- ADXN $0.78
- Revenue Growth
- ONCO 153.70
- ADXN N/A
- 52 Week Low
- ONCO $3.82
- ADXN $6.51
- 52 Week High
- ONCO $1,190.00
- ADXN $13.27
- Technical
- Relative Strength Index (RSI)
- ONCO 40.01
- ADXN 49.41
- Support Level
- ONCO $4.19
- ADXN $8.78
- Resistance Level
- ONCO $5.17
- ADXN $9.89
- Average True Range (ATR)
- ONCO 0.45
- ADXN 0.67
- MACD
- ONCO 0.07
- ADXN -0.03
- Stochastic Oscillator
- ONCO 21.76
- ADXN 43.01
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.